205 related articles for article (PubMed ID: 27586235)
1. Circulating cell-derived microparticles as biomarkers in cardiovascular disease.
Thulin Å; Christersson C; Alfredsson J; Siegbahn A
Biomark Med; 2016 Sep; 10(9):1009-22. PubMed ID: 27586235
[TBL] [Abstract][Full Text] [Related]
2. Microparticles: From Biogenesis to Biomarkers and Diagnostic Tools in Cardiovascular Disease.
Alexandru N; Costa A; Constantin A; Cochior D; Georgescu A
Curr Stem Cell Res Ther; 2017; 12(2):89-102. PubMed ID: 26647911
[TBL] [Abstract][Full Text] [Related]
3. Circulating microparticles in cardiovascular disease: going on stage!
Fernández M; Calligaris SD
Biomarkers; 2019 Jul; 24(5):423-428. PubMed ID: 31068021
[No Abstract] [Full Text] [Related]
4. Cell-derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation?
Baron M; Boulanger CM; Staels B; Tailleux A
J Cell Mol Med; 2012 Jul; 16(7):1365-76. PubMed ID: 22050954
[TBL] [Abstract][Full Text] [Related]
5. Microparticles in atrial fibrillation: a link between cell activation or apoptosis, tissue remodelling and thrombogenicity.
Jesel L; Abbas M; Toti F; Cohen A; Arentz T; Morel O
Int J Cardiol; 2013 Sep; 168(2):660-9. PubMed ID: 23623666
[TBL] [Abstract][Full Text] [Related]
6. Monocyte-derived circulating microparticles (CD14
Chiva-Blanch G; Bratseth V; Ritschel V; Andersen GØ; Halvorsen S; Eritsland J; Arnesen H; Badimon L; Seljeflot I
Int J Cardiol; 2017 Jan; 227():876-881. PubMed ID: 27915085
[TBL] [Abstract][Full Text] [Related]
7. Untargeted Metabolomics in the Discovery of Novel Biomarkers and Therapeutic Targets for Atherosclerotic Cardiovascular Diseases.
Dang VT; Huang A; Werstuck GH
Cardiovasc Hematol Disord Drug Targets; 2018; 18(3):166-175. PubMed ID: 29683098
[TBL] [Abstract][Full Text] [Related]
8. Pattern of endothelial progenitor cells and apoptotic endothelial cell-derived microparticles in chronic heart failure patients with preserved and reduced left ventricular ejection fraction.
Berezin AE; Kremzer AA; Martovitskaya YV; Berezina TA; Gromenko EA
EBioMedicine; 2016 Feb; 4():86-94. PubMed ID: 26981573
[TBL] [Abstract][Full Text] [Related]
9. Microparticles: a component of various diseases.
Budaj M; Poljak Z; Ďuriš I; Kaško M; Imrich R; Kopáni M; Maruščáková L; Hulín I
Pol Arch Med Wewn; 2012; 122 Suppl 1():24-9. PubMed ID: 23222474
[TBL] [Abstract][Full Text] [Related]
10. The pattern of circulating microparticles in patients with diabetes mellitus with asymptomatic atherosclerosis.
Berezin AE; Kremzer AA; Berezina TA; Martovitskaya YV
Acta Clin Belg; 2016 Feb; 71(1):38-45. PubMed ID: 27075791
[TBL] [Abstract][Full Text] [Related]
11. CD3(+)/CD45(+) and SMA-α(+) circulating microparticles are increased in individuals at high cardiovascular risk who will develop a major cardiovascular event.
Chiva-Blanch G; Suades R; Crespo J; Vilahur G; Arderiu G; Padró T; Corella D; Salas-Salvadó J; Arós F; Martínez-González MA; Ros E; Fitó M; Estruch R; Badimon L
Int J Cardiol; 2016 Apr; 208():147-9. PubMed ID: 26859321
[No Abstract] [Full Text] [Related]
12. Microparticles provide a novel biomarker to predict severe clinical outcomes of dengue virus infection.
Punyadee N; Mairiang D; Thiemmeca S; Komoltri C; Pan-Ngum W; Chomanee N; Charngkaew K; Tangthawornchaikul N; Limpitikul W; Vasanawathana S; Malasit P; Avirutnan P
J Virol; 2015 Feb; 89(3):1587-607. PubMed ID: 25410854
[TBL] [Abstract][Full Text] [Related]
13. The Role of Cell-derived Microparticles in Cardiovascular Diseases: Current Concepts.
Stampouloglou PK; Siasos G; Bletsa E; Oikonomou E; Vogiatzi G; Kalogeras K; Katsianos E; Vavuranakis MA; Souvaliotis N; Vavuranakis M
Curr Pharm Des; 2022; 28(21):1745-1757. PubMed ID: 35986552
[TBL] [Abstract][Full Text] [Related]
14. Microparticles: key protagonists in cardiovascular disorders.
Amabile N; Rautou PE; Tedgui A; Boulanger CM
Semin Thromb Hemost; 2010 Nov; 36(8):907-16. PubMed ID: 21069633
[TBL] [Abstract][Full Text] [Related]
15. Microparticles as new markers of cardiovascular risk in diabetes and beyond.
Santilli F; Marchisio M; Lanuti P; Boccatonda A; Miscia S; Davì G
Thromb Haemost; 2016 Aug; 116(2):220-34. PubMed ID: 27173919
[TBL] [Abstract][Full Text] [Related]
16. Cell-derived microvesicles in cardiovascular diseases and antiplatelet therapy monitoring - A lesson for future trials? Current evidence, recent progresses and perspectives of clinical application.
Tomaniak M; Gąsecka A; Filipiak KJ
Int J Cardiol; 2017 Jan; 226():93-102. PubMed ID: 27792994
[TBL] [Abstract][Full Text] [Related]
17. Liquid Biopsies: Microvesicles in Cardiovascular Disease.
Badimon L; Suades R; Vilella-Figuerola A; Crespo J; Vilahur G; Escate R; Padro T; Chiva-Blanch G
Antioxid Redox Signal; 2020 Sep; 33(9):645-662. PubMed ID: 31696726
[No Abstract] [Full Text] [Related]
18. Expression of Blood Cells Associated CD Markers and Cardiovascular Diseases: Clinical Applications in Prognosis.
Haybar H; Maleki Behzad M; Shahrabi S; Ansari N; Saki N
Lab Med; 2020 Mar; 51(2):122-142. PubMed ID: 31340048
[TBL] [Abstract][Full Text] [Related]
19. microRNA expression profile in human coronary smooth muscle cell-derived microparticles is a source of biomarkers.
de Gonzalo-Calvo D; Cenarro A; Civeira F; Llorente-Cortes V
Clin Investig Arterioscler; 2016; 28(4):167-77. PubMed ID: 27363781
[TBL] [Abstract][Full Text] [Related]
20. Microparticles as biomarkers of venous thromboembolic events.
Campello E; Spiezia L; Radu CM; Simioni P
Biomark Med; 2016 Jul; 10(7):743-55. PubMed ID: 27338783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
